REFERENCES
- Olivieri NF, Nathan DG, MacMillan JH, . Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med. 1994;331(9):574–578.
- Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999;341(26):1986–1995.
- Hershko C, Graham G, Bates GW, Rachmilewitz EA. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol. 1978;40(2):255–263.
- DeBaun MR. Secondary prevention of overt strokes in sickle cell disease: therapeutic strategies and efficacy. Hematology Am Soc Hematol Educ Program. 2011;2011:427–433.
- Fung EB, Harmatz P, Milet M, . Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: a report from the multi-center study of iron overload. Am J Hematol. 2007;82(4):255–265.
- Ballas SK. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol. 2001;38(1 Suppl 1):30–36.
- Walter PB, Harmatz P, Vichinsky E. Iron metabolism and iron chelation in sickle cell disease. Acta Haematol. 2009;122(2−3):174–183.
- Lucania G, Vitrano A, Filosa A, Maggio A. Chelation treatment in sickle-cell-anaemia: much ado about nothing? Br J Haematol. 2011;154(5):545–555.
- Vichinsky E, Bernaudin F, Forni GL, . Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol. 2011;154(3):387–397.
- Vichinsky E, Onyekwere O, Porter J, . A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136(3):501–508.
- Voskaridou E, Douskou M, Terpos E, . Deferiprone as an oral iron chelator in sickle cell disease. Ann Hematol. 2005;84(7):434–440.
- Voskaridou E, Plata E, Douskou M, . Deferasirox effectively decreases iron burden in patients with double heterozygous Hb S/β-thalassemia. Ann Hematol. 2011;90(1):11–15.
- Akinsheye I, Alsultan A, Solovieff N, . Fetal hemoglobin in sickle cell anemia. Blood. 2011;118(1):19–27.
- Vlachaki E, Perifanis V, Kondou A, Neokleous N, Teli A, Oikonomou M. Serum uric acid as a predictor factor of the response to deferasirox therapy for patients with β-thalassemia major (abstract #5306). Proceedings of the 53rd American Society of Hematology Meeting and Exhibition, San Diego, CA, USA, December 10–13 2011. Blood. 2011; 118(21).
- Rofail D, Abetz L, Viala M, Gait C, Baladi JF, Payne K. Satisfaction and adherence in patients with iron overload receiving iron chelation therapy as assessed by a newly developed patient instrument. Value Health. 2009;12(1):109–117.
- Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. 2003;102(5):1583–1587.
- Cohen AR, Galanello R, Piga A, Dipalma A, Vullo C, Tricta F. Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol. 2000;108(2):305–312.
- Henter JI, Karlen J. Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia. Blood. 2007;109(12):5157–5159.
- Cappellini MD, Cohen A, Piga A, . A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood. 2006;107(9):3455–3462.
- Piga A, Galanello R, Forni GL, . Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91(7):873–880.
- Oliva EN, Ronco F, Marino A, Alati C, Pratico G, Nobile F. Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients. Transfusion. 2010;50(7):1568–1570.
- Prus E, Fibach E. Effect of iron chelators on labile iron and oxidative status of thalassaemic erythroid cells. Acta Haematol. 2010;123(1):14–20.
- da Silva GB Jr., Liborio AB, Daher Ede F. New insights on pathophysiology, clinical manifestations, diagnosis, and treatment of sickle cell nephropathy. Ann Hematol. 2011;90(12):1371–1379.
- Dubourg L, Laurain C, Ranchin B, . Deferasirox-induced renal impairment in children: an increasing concern for pediatricians. Pediatr Nephrol. 2012;27(11)2115–2122.
- Rheault MN, Bechtel H, Neglia JP, Kashtan CE. Reversible Fanconi syndrome in a pediatric patient on deferasirox. Pediatr Blood Cancer. 2011;56(4):674–676.
- Shichiri M, Matsuda O, Shiigai T, Takeuchi J, Kanayama M. Hypouricemia due to an increment in renal tubular urate secretion. Arch Intern Med. 1982;142(10):1855–1857.